Database / Pharmaceutical impurity
Pharmaceutical impurityGadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt)
Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt) is listed in the pharmaceutical impurity collection. Its represented structure has formula C14H23GdN4O6 and a calculated molecular weight of 500.61 g/mol.
2D chemical structure
Chemical identity
- Catalog name
- Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt)
- Common name
- Gadoteridol Related Compound B
- Chemical name
- 2-[4,7-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+)
- CAS
- Not available
- SMILES
- O=C([O-])CN1CCNCCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3]
- InChI
- InChI=1S/C14H26N4O6.Gd/c19-12(20)9-16-3-1-15-2-4-17(10-13(21)22)6-8-18(7-5-16)11-14(23)24;/h15H,1-11H2,(H,19,20)(H,21,22)(H,23,24);/q;+3/p-3
- InChIKey
- SGPXHPCSEYUXPA-UHFFFAOYSA-K
- Associated API
- Gadoteridol
Record ID: A9493e9f7bfad
Computed properties
C14H23GdN4O6 Molecular formula
500.61 g/molMolecular weight
501.0859 DaMonoisotopic exact mass
142.14 ŲTopological polar surface area
-6.2547 Calculated LogP (Wildman–Crippen)
77.2107 cm³/molMolar refractivity (Wildman–Crippen)
10 countHydrogen-bond acceptors
1 countHydrogen-bond donors
Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD. The SMILES contains 2 disconnected components. Calculations retain all represented components.
Molecular descriptor profile
Structural feature counts
Element composition
Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.
Radar values and percentile reference
| Descriptor | Value | Percentile |
|---|---|---|
| Molecular weight | 500.61 | 85.15 |
| Calculated LogP (Wildman–Crippen) | -6.2547 | 0.86 |
| Topological polar surface area | 142.14 | 87.67 |
| Hydrogen-bond acceptors | 10 | 93.21 |
| Hydrogen-bond donors | 1 | 38.08 |
| Rotatable bonds (strict) | 6 | 69.73 |
Complete molecular descriptors
| Property | Calculated value | Unit / type |
|---|---|---|
| Molecular formula | C14H23GdN4O6 | dimensionless |
| Molecular weight | 500.61 | g/mol |
| Monoisotopic exact mass | 501.0859 | Da |
| Topological polar surface area | 142.14 | Ų |
| Calculated LogP (Wildman–Crippen) | -6.2547 | dimensionless |
| Molar refractivity (Wildman–Crippen) | 77.2107 | cm³/mol |
| Hydrogen-bond acceptors | 10 | count |
| Hydrogen-bond donors | 1 | count |
| Rotatable bonds (strict) | 6 | count |
| Heavy atoms | 25 | count |
| Heteroatoms | 11 | count |
| Rings | 1 | count |
| Aromatic rings | 0 | count |
| Aliphatic rings | 1 | count |
| Saturated rings | 1 | count |
| Aromatic heterocycles | 0 | count |
| Aliphatic heterocycles | 1 | count |
| Saturated heterocycles | 1 | count |
| Aromatic carbocycles | 0 | count |
| Aliphatic carbocycles | 0 | count |
| Fraction of sp³ carbon atoms | 0.7857 | fraction |
| Formal charge | 0 | e |
| Disconnected components | 2 | count |
| Isotopically specified atoms | 0 | count |
| Potential atom stereocenters | 0 | count |
| Unspecified atom stereocenters | 0 | count |
| Spiro atoms | 0 | count |
| Bridgehead atoms | 0 | count |
| Labute approximate surface area | 178.3598 | Ų |
| Valence electrons | 143 | count |
| Radical electrons | 1 | count |
| Bertz complexity | 409.545 | index |
| Balaban J | 0 | index |
Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.
Toxicological services and resources for Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt)
Qualification and safety assessment of Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt)
Explore toxicological qualification of Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt) and ICH M7 mutagenic impurity assessment of Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt) for evaluation of this impurity in its pharmaceutical context.
Where data gaps need to be addressed, resources include read-across assessment for Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt) and acceptable intake and limit justification for Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt). The relevant approach depends on the available evidence, exposure and duration of use.
Related Altox services and technical resources
- ICH M7 Mutagenic Impurity Assessment
- Genotoxic Impurity Risk Assessment
- (Q)SAR Mutagenicity Assessment
- Mutagenic and Non-Mutagenic Impurity Assessment
- Toxicological Qualification of Impurities and Degradation Products
- Toxicological Read-Across Assessment
- Impurity Specification Setting and Limit Justification
- Acceptable Intake (AI) Assessment and Limit Derivation
Identity sources and calculation method
Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.
Discuss an assessment for Gadoteridol Related Compound B (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, monogadolinium salt)
Explore Altox services and software through the Altox Pharma-Hub.